| Formulary Chapter 2: Cardiovascular system - Full Chapter
|
| 02.08.02 |
Oral anticoagulants |
|
|
Apixaban (Eliquis®)
|
Formulary
|
 For preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation. See Primary Care Prescriber Decision Support for DOACs in Atrial Fibrillation.
APCO January 2017.
 For treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. See Guidelines for DOACs for Treatment and Secondary Prevention of VTE.
APCO May 2015.
 For DVT (out of hours), in line with DVT service specification. Prescribe one off initial dose only if presentation of DVT outside of DVT clinic hours.
See Guidelines for DOACs for Treatment and Secondary Prevention of VTE.
APCO September 2018.
 For preventing VTE after total hip or knee replacement in adults in line with NICE TA245.
APCO March 2012.
NB. More information can be found on the OUHFT Anticoagulation & Thrombosis page.
|
CoaguChek Testing Strips
(INR self-testing)
|
 Restricted
|
Restricted to patients who meet the following criteria:
- To be on long-term oral anticoagulation.
- To have sufficient eye sight to enable them to use the coagulometer.
- To be sufficiently dextrous to carry out self-testing. (Training may be considered for patient carers or next of kin who meet the eye sight and dexterity criteria.)
- To have GP support for the prescribing of strips.
- To already be dosed by the Oxfordshire Anticoagulation Service (JR, Churchill or Horton hospitals).
- To be able to afford the coagulometer (about £500 for the CoaguCheks and approximately £20 for enough quality control solutions for approximately one year, not including the training programme).
The patient would have to receive suitable training to carry out self-testing and this would normally be provided by the hospital anticoagulation service if self-testing is agreed appropriate.
APCO September 2018.
|
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Red: Medicines which should only be prescribed in secondary care by a specialist. |
|
Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred. |
|
Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO). |
|
Green: Medicines which are suitable for initiation and ongoing prescribing within primary care. |
|
Brown: Medicines which should only be prescribed in restricted circumstances. |
|
Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety. |
|
not used |
|
|
